ScholarIQanswers from OpenAlex & ORCID
Douglas I. Lin
ResearcherPublications, citations & collaboration network
Douglas I. Lin is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Douglas I. Lin have?
ScholarIQindexed works
Douglas I. Lin has 248 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Douglas I. Lin have?
ScholarIQcitation count
Douglas I. Lin has 5,196 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Douglas I. Lin?
ScholarIQh-index
Douglas I. Lin has an h-index of 36 in OpenAlex.
What is the i10-index of Douglas I. Lin?
ScholarIQi10-index
Douglas I. Lin has an i10-index of 73 in OpenAlex.
What is the ORCID of Douglas I. Lin?
ScholarIQorcid
The ORCID for Douglas I. Lin is on the source record.
What is the OpenAlex record for Douglas I. Lin?
ScholarIQopenalex
The OpenAlex for Douglas I. Lin is on the source record.
What are the most-cited papers on Douglas I. Lin?
ScholarIQmost cited works
High grade serous ovarian carcinomas originate in the fallopian tube
Sana Intidhar Labidi‐Galy, Eniko Papp, Dorothy Hallberg, Noushin Niknafs, Vilmos Adleff, Michaël Noë, Rohit Bhattacharya, Marián Novak, Siân Jones, Jillian Phallen, Carolyn Hruban, Michelle S. Hirsch, Douglas I. Lin, Lauren E. Schwartz, Cécile L. Maire, Jean‐Christophe Tille, Michaela Bowden, A. Ayhan, Laura D. Wood, Robert B. Scharpf, Robert J. Kurman, Tian-Li Wang, Ie‐Ming Shih, Rachel Karchin, Ronny Drapkin, Victor E. Velculescu
p63 Is a Prostate Basal Cell Marker and Is Required for Prostate Development
Sabina Signoretti, David Waltregny, James R. Dilks, Beth Isaac, Douglas I. Lin, Levi A. Garraway, Annie Yang, Rodolfo Montironi, Frank McKeon, Massimo Loda
Phosphorylation-Dependent Ubiquitination of Cyclin D1 by the SCFFBX4-αB Crystallin Complex
Douglas I. Lin, Olena Barbash, Suresh Kumar, Jason D. Weber, J. Wade Harper, Andres J. Klein–Szanto, Anil K. Rustgi, Serge Y. Fuchs, J. Alan Diehl
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
Elizabeth M. Swisher, Tanya T. Kwan, Amit M. Oza, Anna V. Tinker, Isabelle Ray‐Coquard, Ana Oaknin, Robert L. Coleman, Carol Aghajanian, Gottfried E. Konecny, David M. O’Malley, Alexandra Léary, Diane Provencher, Stephen Welch, Lee-may Chen, Andrea E. Wahner Hendrickson, Ling Ma, Prafull Ghatage, Rebecca Kristeleit, Oliver Dorigo, Ashan Musafer, Scott H. Kaufmann, Julia A. Elvin, Douglas I. Lin, Setsuko K. Chambers, Erin Dominy, Lan-Thanh Vo, Sandra Goble, Lara Maloney, Heidi Giordano, Thomas Harding, Alexander Dobrovic, Clare L. Scott, Kevin Lin, Iain A. McNeish
Mutations in Fbx4 Inhibit Dimerization of the SCFFbx4 Ligase and Contribute to Cyclin D1 Overexpression in Human Cancer
Olena Barbash, Petia Zamfirova, Douglas I. Lin, Xiangmei Chen, Yang Ke, Hiroshi Nakagawa, Fengmin Lu, Anil K. Rustgi, J. Alan Diehl